Section 4 of 6
Clinical evidence
259 evidence topics · 42 sources
Study summaries
IB1001-303
Objective
Purpose and primary objective in the trial protocol
Secondary and exploratory objectives in the trial protocol
Symptomatic parent study and long-term extension phase
“The IB1001-303 clinical trial was separated into two study phases to enable the investigation of the symptomatic (parent study) and long-term (open-label extension phase) safety and efficacy of levacetylleucine.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The results of the parent study are reported below and are closed to new participants. The extension phase is ongoing.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Countries and number of centers
Participating centers named in the publication
“We thank the study teams and co-investigators from Comenius University in Bratislava, Hospital La Paz Madrid, Justus Liebig University Giessen, Massachusetts General Hospital, Nottingham University Hospital NHS Trust, Royal Papworth NHS Foundation Trust, University Hospital of L. Pasteur Kosice, University of Bern, University of Cologne, and UTHealth Houston.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Study locations in the registry record
Study dates in the registry record
| Field | Registry value |
|---|---|
| Study start (actual) | “2025-03-18” |
| Primary completion (estimated) | “2027-12-31” |
| Study completion (estimated) | “2028-06-01” |
| First posted | “2024-11-04” |
| Last update posted | “2025-07-03” |
European Union trial start and recruitment start by member state
| Member state | Decision date | Trial start date | Recruitment start date |
|---|---|---|---|
| Germany | “25/03/2025” | “13/05/2025” | “13/05/2025” |
| Spain | “25/03/2025” | “13/05/2025” | “29/05/2025” |
| Slovakia | “26/03/2025” | “13/05/2025” | “19/05/2025” |
Planned number of centers and participants traveling from other countries
Study design
Prescribing information: randomized, double-blind, placebo-controlled, two-period crossover design
Baseline period, treatment periods, and visit schedule
“The study consisted of a baseline period followed by two 12-week treatment periods (figure 1). In the baseline period, there were two visits, which occurred 14–21 days apart. At the second baseline visit (visit 2), eligible patients were randomly assigned to receive either levacetylleucine or placebo in period 1, which they immediately commenced and received for 84–91 days. At the end of the first treatment period (visit 4), patients immediately crossed over to receive the opposite study drug in period 2 for 84–91 days. Two visits occurred in each period (period 1: visit 3 and 4; period 2: visit 5 and 6).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Randomization method
“Randomisation was done centrally by Medpace, a clinical research organisation, with the use of computerised interactive response technology.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The study used a permuted block design for randomisation of four-patient block sizes. The live randomisation list was generated by an independent statistician based on the approved randomisation plan.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“As the trial was a crossover design, in which each patient received levacetylleucine and placebo and therefore served as their own control, no stratification by age was done.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Masking
“All participants, investigators, and assessors were blinded to group assignment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients, their families, the study team, the principal investigator, and the sponsor were blinded to the randomisation scheme and the sequences to which each patient was assigned until after database lock and study unblinding.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The success of masking was not formally assessed, given its high potential to introduce bias and lead to misinterpretations of participant and caregiver perceptions and responses.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Immediate crossover without a washout period: rationale in the trial protocol
Screening pathways for participants with and without recent use of prohibited medications
Data monitoring and availability of the protocol and statistical analysis plan
“The safety, integrity, and feasibility of the trial were also monitored by an independent data safety monitoring board consisting of two clinicians and a statistician.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The study protocol and statistical analysis plan are available in the appendix (pp 13–162, 164–227).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Funding and role of the sponsor
“The funder collaborated with authors during study design but had no role in data collection, data analysis, data interpretation, or writing of the report.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The study was funded by IntraBio.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Finally, we thank Taylor Fields for her leadership of and dedication to the levacetylleucine development programme and for assistance in carrying out clinical trials and for writing and editorial assistance with the manuscript.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Master protocol published for the Niemann-Pick disease type C trial: rationale for the crossover design
“Details of the methods, rationale, design, and oversight of the master study protocol have been previously published.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Given the extreme heterogeneity of the disease, a crossover study design is utilized so that each patient serves as their own control and the clinical meaningfulness of the effect can be assessed for each patient.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Prescribing information: age, diagnosis, and ataxia at baseline
Key inclusion criteria: genetic confirmation, ataxia severity, and body weight
“Eligible patients were aged 4 years or older with a genetically confirmed diagnosis of ataxia-telangiectasia; had a SARA score of 7–34 and were either within the 2–7 range of the gait subtest of the SARA scale or were able to perform the 9-hole peg test with their dominant hand in a time of 20–150 sec; and weighed 15 kg or more at screening.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Inclusion criteria: stable background medications and therapies
Inclusion criteria: contraception
Exclusion criteria
Exclusion criteria: washout of prohibited medications
Exclusion criteria: prohibited medications at European Union sites
Treatment
Prescribing information: dosage and duration in Trial 2
Weight-tiered dosing in the trial protocol
Dose per kilogram for participants weighing less than 35 kg
Formulation and preparation
Matching placebo
“The placebo was developed to have the same colour, taste, appearance, and solubility properties as the active agent, and both were packaged identically as granules in a sachet for suspension in 40 mL of water, orange juice, or almond milk, administered with identical dosing regimens.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Concomitant medications and therapies
Study outcomes
Rationale for using the scale for the assessment and rating of ataxia as the primary endpoint
Primary endpoint defined in the trial protocol
Primary outcome measure in the registry record
SARA items, score range, and meaningful change as described by the investigators
“The primary endpoint was the SARA, an eight-item (gait, stance, sitting, speech disturbance, finger chase, nose-finger test, fast alternating hand movement, and heel-shin slide) clinical rating scale ranging from 0 to 40, in which 0 is the best neurological status and 40 the worst.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“for which a 1-point change has been validated as representing a clinically meaningful change in functioning (gain or loss of complex function which is relevant to the patient's everyday life).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
SARA development and validation in spinocerebellar ataxia
“The authors devised the Scale for the Assessment and Rating of Ataxia (SARA) and tested it in two trials of 167 and 119 patients with spinocerebellar ataxia.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Interrater reliability was high, with an intraclass coefficient (ICC) of 0.98. Test-retest reliability was high with an ICC of 0.90. Internal consistency was high as indicated by Cronbach's alpha of 0.94.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The Scale for the Assessment and Rating of Ataxia is a reliable and valid measure of ataxia, making it an appropriate primary outcome measure for clinical trials.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
SARA reliability and validity in ataxias other than spinocerebellar ataxia
“To this end, 64 patients with various ataxia disorders or stable cerebellar lesions were rated independently by two investigators.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Inter-rater and intrarater reliability were very high with ICCs of 0.98 and 0.99. Internal consistency was high indicated by Cronbach's alpha of 0.97.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The results suggest that SARA is a reliable and valid measure of ataxia in non-SCA ataxia patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
SARA in children: age dependency of scores and of interobserver agreement
“In typically developing children, age was the only variable that revealed a relationship with SARA scores (p<0.001). The youngest children revealed the highest scores and the highest variation in scores (<8y; p<0.001). After 11 years of age, pediatric scores approached adult outcomes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In typically developing European children, both SARA scores and interobserver agreement are age-dependent.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“ICARS, SARA, BARS and PEG-board test outcomes were age-dependent until 12.5, 10, 11, and 11.5 years of age respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In healthy children, ataxia rating scales are reliable, but should include age-dependent interpretation in children up to 12 years of age.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
SARA in ataxia-telangiectasia: recommendation of a rating-scale review panel
“for ataxia telangiectasia: ICARS and SARA;” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The main limitations of these instruments include the limited assessment of patients in the more severe end of the spectrum and children.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
SARA in ataxia-telangiectasia: validation status and correlation with a disease-specific scale in adults
“However, the SARA score remains unvalidated specifically for use in A-T and is not without its limitations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The weighting of the total score is also disproportionately influenced by the gait domain. Many classical A-T patients lose ambulation by their teenage years, and it is unclear how this influences the assessment of disease progression in non-ambulant patients who continue to report clinical deterioration” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We found a strong correlation between A-T NEST and the established SARA score, validating the use of A-T NEST and SARA in capturing the natural history of A-T patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
SARA in ataxia-telangiectasia: annual progression in adults
“We analysed longitudinal Scale for the Assessment and Rating of Ataxia (SARA) data from the largest published adult AT cohort to date (n = 82, age > 16 years).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Neurological impairment progressed with a mean SARA increase of 0.38 points/year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“SARA remains a useful outcome measure but may underestimate progression in advanced disease and non-cerebellar domains.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Minimal clinically important difference of the SARA: thresholds cited by the investigators
Minimal clinically important difference of the SARA: 1-point threshold derived from levacetylleucine trials in lysosomal storage disorders
“We analyzed data from three clinical trial cohorts (IB1001-201, IB1001-202, and IB1001-301) of patients with Niemann–Pick disease type C (NPC) and GM2 Gangliosidoses (Tay–Sachs and Sandhoff disease) comprising 122 patients and 703 visits.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Further qualitative analyses of the patient/caregiver interviews demonstrated a 1-point or greater change on SARA to be a clinically meaningful improvement which is directly relevant to the patient’s everyday functioning and quality of life.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A 1-point change represents a clinically meaningful transition reflecting the gain or loss of complex function.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Minimal clinically important difference of the SARA: 1.5-point threshold in cerebellar ataxias
“Sixty-two individuals with cerebellar ataxias participated in a home-exercise clinical trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The MCID for SARA using anchor-based method was 1.75. The distribution-based method and distribution-based mapping identified a median MCID score of 1.23.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Synthesizing methods, we determined an MCID of 1.5 points.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Responsiveness of the SARA over one year in spinocerebellar ataxia
“Within the 1-year follow-up period, SARA, INAS, and SCAFI but not EQVAS indicated worsening in the whole group and in the groups with subjective (PGI) worsening.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“SARA and EQVAS performed best to distinguish groups classified as worse by PGI.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Functional SARA: definition in the prescribing information
Functional SARA: key secondary endpoint for the United States in the trial protocol
Functional SARA: inclusion at FDA request as described by the investigators
“At the request of the US Food and Drug Administration (FDA), in the USA, the FDA functional SARA (f-SARA), which consisted of the axial domains (gait, stance, sitting, speech disturbance) rescored on a scale ranging from 0 to 16, in which 0 is the best neurological status and 16 is the worst, was included as a secondary endpoint.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Functional SARA: FDA rationale for domain selection and rescoring in the Niemann-Pick disease type C review
Functional SARA: FDA-recommended rescoring of the four SARA domains
Functional SARA: FDA interpretation of a 1-point change and correlation with the SARA in the Niemann-Pick disease type C trial
Functional SARA: origin and content validity in spinocerebellar ataxia
“The resulting modification of the SARA, the functional SARA (f-SARA), is a 4-item scale that assesses Gait, Stance, Sitting, and Speech. Each of the 4 items is rated on an ordinal scale from 0 to 4, where 0 indicates normal or unimpaired function, and higher responses indicate progressive impairment. The total f-SARA score is the sum of the 4 individual items (16 points).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The f-SARA was developed based on recommendations from a regulatory body to capture unequivocal and compelling changes that might be functionally meaningful and reflect treatment effect in individuals with SCA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“HCPs with previous f-SARA exposure considered that a 1- to 2-point change on the f-SARA total score and a 1-point change on the item score was meaningful.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Functional SARA: psychometric properties and meaningful change threshold in spinocerebellar ataxia
“The ICC was 0.91 (0.88–0.93) for the f-SARA in the cohort consisting of all SCA subjects and ranged from 0.73 (0.65–0.79) for sitting to 0.92 (0.89–0.94) for gait” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Regarding the intra-individual meaningful change thresholds for the f-SARA total score, findings reported herein, and as triangulated with natural history data reports by Moulaire et al., support a 1-point annual worsening as clinically meaningful” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In conclusion, the psychometric data reported herein support the use of the f-SARA as a reliable COA to measure disease progression over a 1-year period or longer, noting that the sitting item appeared as the least responsive of the 4 f-SARA items.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
SARA and fSARA treatment differences in the Niemann-Pick disease type C trial of levacetylleucine
“The primary end point was the total score on the Scale for the Assessment and Rating of Ataxia (SARA; range, 0 to 40, with lower scores indicating better neurologic status).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean (±SD) change from baseline in the SARA total score was -1.97±2.43 points after 12 weeks of receiving NALL and -0.60±2.39 points after 12 weeks of receiving placebo (least-squares mean difference, -1.28 points; 95% confidence interval, -1.91 to -0.65; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Interpretability of the SARA in young children: FDA position and protocol subgroup analysis
Secondary and exploratory endpoints listed in the trial protocol
ICARS and NeuroQOL-UEF designations changed in the statistical analysis plan
International Cooperative Ataxia Rating Scale
“The International Cooperative Ataxia Rating Scale (ICARS; a 19-domain scale with symptoms grouped by postural and gait disturbances, limb ataxia, dysarthria, and oculomotor disorders, ranging from 0 to 100, in which 0 is the best neurological status and 100 the worst) was also used to quantify the level of neurological impairment and changes in overall” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“neurological symptoms and status.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“With the long-term goal of double-blind controlled trials-multicentric and international-an ad hoc Committee of the World Federation of Neurology has worked to propose a one-hundred-point semi-quantitative International Cooperative Ataxia Rating Scale (ICARS).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The validation of this scale is in progress.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We recruited 63 patients with ataxia, aged 10.76 ± 3.2 years, followed at 6 international AT centers, 49 of them (77.8%) with classical AT.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In addition we showed that ataxia can be reliably measured in children with AT by using ICARS.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Spinocerebellar Ataxia Functional Index
“Cerebellar function was assessed using the Spinocerebellar Ataxia Functional Index (SCAFI), comprising the timed 8-Meter Walk Test (8MWT), the timed 9-Hole Peg Test (9HPT) with the dominant and non-dominant hand, and the number of spoken PATA repetitions within 10 seconds; each test was done twice.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The Z-scores of each subtest correlated well with the Scale for the Assessment and Rating of Ataxia (SARA), the Unified Huntington's disease Rating Scale functional assessment, and disease duration.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The proposed functional measures and their composite SCAFI have favorable properties to assess patients with spinocerebellar ataxia.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Clinical Global Impression scales
Quality-of-life instruments and exit interviews
“Subjective impairment and quality of life were evaluated by use of the Clinical Global Impression of Severity (CGI-S) and Improvement Scale (completed by the investigators, caregivers, and patients)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Safety assessments
Statistical analysis description
Number of participants (Planned and analyzed)
Sample size calculation in the trial protocol
Estimated enrollment in the registry record
| Field | Registry value |
|---|---|
| Enrollment (estimated) | “60” |
Participants screened, randomized, and analyzed
| Population | Participants |
|---|---|
| Screened | “77”View highlighted excerpt for this quote |
| Excluded for not meeting inclusion criteria | “Four”View highlighted excerpt for this quote |
| Enrolled and randomly assigned | “73”View highlighted excerpt for this quote |
| Assigned to levacetylleucine followed by placebo | “36”View highlighted excerpt for this quote |
| Assigned to placebo followed by levacetylleucine | “37”View highlighted excerpt for this quote |
| Included in the primary analysis and safety sets | “73”View highlighted excerpt for this quote |
Description of analysis sets
Analysis populations
“Safety and efficacy analyses were done in all randomly assigned patients who received at least one dose of study medication, and a linear mixed-effects model was used to account for data missing at random.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Primary analysis model as reported in the publication
“The primary endpoint of the treatment was evaluated using a linear mixed-effects model with the SARA score at the end of each period as the independent variable. The model included baseline (visit 2 SARA score), sequence, period, treatment, and the interaction between baseline and period as fixed effects. Two-sided p values of the null hypothesis were calculated and a significance level of 0·05 was used to judge statistical significance. This method of analysis accounts for any crossover period effects, allows for data missing at random, and evaluates the within-patient differences.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Primary analysis model in the statistical analysis plan
Primary estimand and intercurrent events
Handling of missing data
“For the SARA/functional SARA, last observation carried forward is applied for one patient to handle missing data at visit 6.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Only reported data were included in the secondary endpoint analyses.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Significance level and multiplicity
“Because there was no prespecified plan for adjustment of the widths of CIs for multiple comparisons, results for secondary endpoints are presented as point estimates and 95% CIs without p values and no definite conclusions can be drawn from these data.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Analysis of secondary endpoints
“The SCAFI and ICARS secondary endpoints were evaluated as per the primary endpoint. The change from baseline to the end of period 1 for the two treatment groups was assessed for the Clinical Global Impression of Improvement (CGI-I).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prespecified subgroups and interim analysis
“Naïve versus non-naïve as determined at screening” (opens the source at this quote in a new tab)
“Age (pediatric versus adult)” (opens the source at this quote in a new tab)
“Gender (male versus female)” (opens the source at this quote in a new tab)
“Region (US versus rest of world)” (opens the source at this quote in a new tab)
“There is no interim analysis planned.” (opens the source at this quote in a new tab)
“For the primary and each secondary endpoint, there were separate evaluations within key subgroups predefined in the statistical analysis plan (the trial was not powered for conclusions in these subgroups).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Screening, randomization, and inclusion in the analysis
“Four patients were excluded (not meeting inclusion criteria) and 73 were enrolled and randomly assigned (36 to levacetylleucine followed by placebo and 37 to placebo followed by levacetylleucine. 73 patients were included in the primary analysis and safety sets.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Withdrawals and their reasons
“One patient in the levacetylleucine followed by placebo group withdrew in period 1 between visit 2 and visit 3 due to a physician's decision after confirmation of an unrelated serious adverse event which emerged during the baseline period, but was not formally diagnosed until shortly after the patient began study drug (T-cell type acute leukaemia). Two patients in the placebo to levacetylleucine group withdrew (one in period 2 between visit 5 and visit 6 due to an unrelated serious adverse event [lower respiratory tract chest infection] and one in period 2 between visit 4 and visit 5 due to an unrelated serious adverse event [diffuse large B-cell lymphoma]). 70 patients completed the study and 73 were included in analyses.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prescribing information: completion and missing assessments
Congress abstract submitted before data availability: number randomized
Congress results abstract: number enrolled
Baseline characteristics
Prescribing information: age, sex, and race
Demographics and baseline characteristics by treatment sequence
Baseline scores on the efficacy and quality-of-life measures
Representativeness of the trial population
Efficacy results
Primary endpoint: fSARA total score, prescribing information
fSARA total score by period and treatment sequence, prescribing information
| Variable | Treatment Sequence 1: AQNEURSA then placebo | Treatment Sequence 2: placebo then AQNEURSA |
|---|---|---|
| Baseline, participants | “N=36” | “N=37” |
| Baseline, mean (SD) | “7.3 (2.6)” | “8.5 (2.5)” |
| Period I, participants | “N=34” | “N=37” |
| Period I, mean (SD) | “6.6 (2.8)” | “8.5 (2.6)” |
| Period II, participants | “N=35” | “N=35” |
| Period II, mean (SD) | “7.0 (3.1)” | “7.8 (2.7)” |
Least squares mean fSARA score by treatment, prescribing information
| Treatment | Least squares mean fSARA score (SE) |
|---|---|
| AQNEURSA | “7.2 (0.1)” |
| Placebo | “7.8 (0.1)” |
| Treatment difference (95% CI) | “-0.6 (-0.9, -0.2)” |
Change in fSARA score by period within each treatment sequence, prescribing information
Primary endpoint: SARA total score, peer-reviewed publication
“The mean change in the SARA total score with levacetylleucine was -1·92 (SD 2·81) versus -0·14 (2·38) with placebo (linear mixed model treatment effect -1·88 [SD 0·41], 95% CI -2·70 to -1·06; p<0·0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Primary and secondary efficacy endpoints at end of treatment, peer-reviewed publication
“Linear mixed model treatment effect was computed for the SARA primary endpoint and the functional SARA, SCAFI, and ICARS secondary endpoints (but not other secondary endpoints).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The change from baseline is the reported change from a score of 4 (no change).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
SARA change by period: placebo in period 1 and placebo after levacetylleucine in period 2
“Patients who received placebo in period 1 experienced no significant change at 12 weeks, with a mean change in SARA score of –0·14 points (SD 1·92). By contrast, patients who received levacetylleucine followed by placebo (n=35) had an increase in SARA score of 1·81 (SD 3·12) during period 2 on placebo, which effectively served as a washout from levacetylleucine, reflecting a deterioration in neurological signs and symptoms when treatment with levacetylleucine was stopped.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Secondary endpoints: fSARA, investigator CGI-I, ICARS, and SCAFI, peer-reviewed publication
“The mean change on the FDA f-SARA was –0·65 (SD 1·16) with levacetylleucine versus –0·10 (1·02) with placebo (least square mean difference of –0·57 (0·17, 95% CI –0·92 to –0·23; p=0·001; table 2). Relative to placebo, levacetylleucine demonstrated significant improvements on the CGI-I investigators’ scale (mean change –0·4, 95% CI –0·7 to –0·02; p=0·02) and ICARS (mean difference –2·84, 95% CI –4·87 to –0·81; p=0·003; table 2). The patients’ CGI-I scale and the SCAFI, including 8MWT, 9HPT-D (dominant hand), 9HPT-ND (non-dominant hand), and PATA domains, numerically favoured the levacetylleucine group (table 2).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Subgroup analyses of the SARA total score
“Figure 3B displays results for the primary SARA endpoint in the predefined subgroups showing 95% CIs. There is no evidence of heterogeneity in treatment effect across subgroups that would suggest a differential treatment effect across the population. Instead, across all subgroups, there were consistent improvements with levacetylleucine versus placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Comparison of the observed effect with reported thresholds, as stated by the investigators
“the mean change on levacetylleucine and the treatment effect with levacetylleucine versus placebo are larger than all reported thresholds.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For patients randomly assigned to sequence 1 (levacetylleucine to placebo), the improvements of levacetylleucine treatment observed in period 1 were lost in period 2 (consistent with the drug's pharmacological and pharmacokinetic action), as patients worsened and returned to their baseline status.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Primary endpoint: SARA total score, company-reported topline results
Secondary endpoints: ICARS and investigator CGI-I, company-reported topline results
SARA and fSARA treatment differences, company-reported at FDA approval
Primary and secondary endpoints, congress results abstract
Health-related quality of life and patient-reported outcomes
Patient-reported, caregiver-reported, and quality-of-life endpoints at end of treatment
EQ-5D-5L in adults and EQ-5D-Y in participants younger than 18 years
“Quality of life improvements with levacetylleucine versus placebo were captured for adult patients by the EQ-5D-5L assessment, which demonstrated a decrease” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“in patient-reported rates of moderate to severe problems with mobility, a decrease in their pain and discomfort, and an increase in patient-reported ability to do usual activities.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For paediatric patients, the EQ-5D-Y (used for patients aged <18 years) showed improvements in mobility and self-care with levacetylleucine. On the EQ-VAS, there was improvement with levacetylleucine, compared with a worsening on placebo (table 2).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Exit interviews: proportions reporting improvement and meaningful change
“57 (81%) of 70 exit interviews completed by participants or caregivers reported improvement in patients’ neurological signs and symptoms during the study while on levacetylleucine. 46 (66%) of 70 responders reported that the changes during the IB1001-303 parent study were relevant or meaningful to the patient's everyday life and highlighted how these functional improvements not only resulted in meaningful changes for the patients but also provided adjunct benefits to the caregivers, families, coworkers, or classmates. 29 (41%) of 70 exit interviews specifically noted how the improvements during the trial were relevant for their safety and everyday activities.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Exit interviews: improvements reported by participants and caregivers
Safety results
Prescribing information: thrombocytopenia in one participant during Trial 2
Treatment-emergent adverse events, serious adverse events, and deaths
Discontinuations and events assessed as related to levacetylleucine
“No treatment-emergent adverse events led to premature discontinuation of the study drug. No treatment-emergent adverse events occurred in more than 10% of patients on levacetylleucine. Two patients had 3 treatment-emergent adverse events that were assessed as related to levacetylleucine (diarrhoea [mild], eczema [mild], and insomnia [moderate]). These events were all transient.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treatment-emergent adverse events by system organ class
“Data are included for all patients who were enrolled and received at least one dose of treatment. Data are reported by what product was being received at the time of event. Adverse events are coded according to MedDRA, version 27.1.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treatment-emergent adverse events reported in two or more participants during either treatment
Laboratory tests, vital signs, and electrocardiograms
“No study drug-related serious adverse events or deaths occurred in either group. Results of plasma and urine tests, vital signs, and ECG recordings were normal or rated as clinically non-significant.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
FDA summary of adverse reactions in ataxia-telangiectasia
Safety, company-reported at FDA approval
Study limitations
Summary
IB1001-303 randomized 73 participants at ten centers to a two-period crossover with 12 weeks of each treatment and an immediate crossover, with no washout between periods. The protocol chose an analysis that does not require a washout, and the publication describes the placebo period that followed levacetylleucine as having effectively served as a washout. The publication and the prescribing information report no result of a test for carryover or sequence effects. In the prescribing information, mean baseline fSARA was 7.3 in the sequence that started with levacetylleucine and 8.5 in the sequence that started with placebo.
The endpoint reported differs by source. The protocol names the 40-point SARA as the primary endpoint in all jurisdictions besides the United States and the 16-point functional SARA (fSARA) as a key secondary endpoint for the United States. The publication reports a SARA treatment effect of -1.88 points (95% CI -2.70 to -1.06), with mean changes of -1.92 on levacetylleucine and -0.14 on placebo. The prescribing information reports an fSARA treatment difference of -0.6 (95% CI -0.9 to -0.2; two-sided p = 0.0013) and gives no numerical SARA result. The fSARA p value is 0.001 in the publication, and the company's approval release gives a two-sided p value below 0.001.
The sample size calculation used a one-sided significance level of 5% and assumed a 1.0-point SARA difference, a threshold taken from an analysis of the sponsor's trials in lysosomal storage disorders; an independent estimate of the SARA minimal clinically important difference is 1.5 points. No adjustment for multiple comparisons was applied, and the statistical analysis plan classes every evaluation other than the primary endpoint as exploratory. The statistical analysis plan specifies descriptive summaries for the ICARS, and the publication reports a model-based ICARS treatment effect with a p value. Success of masking was not assessed. The SARA has not been validated specifically in ataxia-telangiectasia, and pediatric SARA scores are age-dependent; 47 of 73 participants (64%) were younger than 18 years.
The controlled comparison lasted 12 weeks per treatment, 55 of 73 participants (75%) were White, and eligibility required an age of 4 years or older and a SARA score of 7 to 34. Long-term efficacy and safety data depend on the open-label extension phase, which was ongoing at publication. The results were published in a peer-reviewed journal in July 2026; the trial was funded by IntraBio, and the publication acknowledges an IntraBio employee for writing and editorial assistance. The ClinicalTrials.gov record lists an estimated enrollment of 60, was last updated in July 2025, and carries no posted results. One congress abstract, submitted before data were available, states that 74 participants were randomized, and the congress results abstract states that no serious adverse events occurred, whereas the publication reports 73 randomized participants and three withdrawals associated with serious adverse events judged unrelated to treatment.
Limitations stated by the investigators
“This study has several limitations. First, the study was designed to investigate the symptomatic effects of levacetylleucine; data from the ongoing extension phase will provide further insights into its impact on ataxia-telangiectasia disease progression and continued data on the long-term safety of levacetylleucine for ataxia-telangiectasia. Second, the focus on symptomatic endpoints excluded patients younger than 4 years, asymptomatic patients, or patients with advanced disease states who would not be reliably able to complete functional assessments. Third, the study included paediatric patients; although all study assessments have been used previously in paediatric populations, not all study assessments are formally validated for use in paediatric populations. Fourth, most patients in this trial were White and of North American or European descent, and data on patients of other ethnicities were scarce or absent.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Fifth, there is no validated biomarker for ataxia-telangiectasia or a surrogate endpoint which is indicative of clinical improvement. Sixth, as with all clinical trials implementing null hypothesis significance testing, the design and sample size cannot exclude the potential of type I error. Finally, the study duration was not long enough to investigate the effects of levacetylleucine on other key features of ataxia-telangiectasia, such as immunological defects and oncological risks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Multiplicity and the exploratory status of secondary endpoints
IB1001-203
Objective
Secondary and exploratory objectives of the parent study
Symptomatic and long-term questions addressed by the parent study and the extension phase
“The two treatment sequences in the parent study and extension phase enable the investigation of both the symptomatic (6 week) and long-term (1 year) safety and efficacy of treatment with N-acetyl-l-leucine.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Registry dates and status
| Field | Quoted record |
|---|---|
| Study start (actual) | “2020-01-08” |
| Primary completion (actual) | “2025-02-11” |
| Study completion (actual) | “2025-10-27” |
| Results first posted | “2026-03-25” |
| Recruitment status | “Terminated” |
Registry study sites
| Country | Site |
|---|---|
| United States | “University of California - Los Angeles” |
| Germany | “University of Giessen” |
| Spain | “Hospital Universitario La Paz” |
| United Kingdom | “Royal Papworth Hospital NHS Foundation Trust” |
Period of participation and number of hospitals
Termination before target recruitment
Study design
Multinational, open-label, rater-blinded phase 2 study
| Design field | Quoted record |
|---|---|
| Phase | “Phase 2” |
| Allocation | “Non-Randomized” |
| Interventional model | “Single Group Assignment” |
| Masking | “Single (Outcomes Assessor)” |
Baseline, treatment, and washout periods of the parent study
Post-treatment washout as the within-participant control
Blinded rating of video recordings
“The CI-CS assessment is ultimately performed by independent, blinded raters who compare videos of the primary anchor test from three periods: baseline, the end of treatment, and the end of a post-treatment washout.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pairs A, B, and C are reviewed by the raters in random order.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The raters will be blinded in this way to reduce detection and performance biases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Choice of an open-label design over a placebo-controlled crossover design
“A formal feasibility study was initiated by the Sponsor that demonstrated that a long-term, randomized, double-blind, placebo-controlled, crossover study would be difficult to recruit and carry out without changes to the study design.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This was largely attributed to the known, widespread, off-label/unlicensed use of N-acetyl-dl-leucine (Tanganil®).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In order to assure the feasibility of recruitment, an open-label study schema is used.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Screening for prior use of the racemate
“Given the known unlicensed use of the racemate (Tanganil®), for all patients, a urine sample will be taken at visit 1 to detect N-acetyl-d-leucine using a validated liquid chromatography mass spectrometry/mass spectrometry method.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients who fail two urine N-acetyl-d-leucine tests (e.g., visit 1 and repeat visit 1) are ineligible for the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Extension phase: two 1-year treatment periods separated by a washout
One of three trials under a master protocol
“The IB1001-201 (NPC), IB1001-202 (GM2), and IB1001-203 (A-T) clinical trials are separate multinational, multicenter, open-label, rater-blinded phase II studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Data from the three clinical trials will be analyzed separately.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Independent data safety monitoring board
“The safety, integrity, and feasibility of the trial is monitored by an independent data safety monitoring board (DSMB) consisting of three independent, non-participating members (including two clinicians and a statistician).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Key inclusion criteria
Age limit by region in the master protocol
Key exclusion criteria
Prohibited medications and washout
| Prohibited medication | Quoted record |
|---|---|
| Aminopyridines | “Aminopyridines (including sustained-release form);” |
| Racemate | “N-Acetyl-DL-Leucine (e.g. Tanganil®);” |
| L-enantiomer from another source | “N-Acetyl-L-Leucine (prohibited if not provided as IMP);” |
| Riluzole | “Riluzole;” |
| Gabapentin | “Gabapentin;” |
| Varenicline | “Varenicline;” |
| Chlorzoxazone | “Chlorzoxazone;” |
| Sulfasalazine | “Sulfasalazine;” |
| Rosuvastatin | “Rosuvastatin.” |
Entry to the extension phase
Treatment
Dose by age and body weight
| Age and weight group | Registry description of treatment |
|---|---|
| 13 years or older | “Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day).” |
| 6 to 12 years, 15 to less than 25 kg | “Patients aged 6-12 years weighing 15 to <25 kg will take 2 g per day: 1 g in the morning and 1 g in the evening.” |
| 6 to 12 years, 25 to less than 35 kg | “Patients aged 6-12 years weighing 25 to <35 kg will take 3 g per day: 1 g in the morning, 1 g in the afternoon, and 1 g in the evening.” |
| 6 to 12 years, 35 kg or more | “Patients aged 6-12 years weighing ≥35 kg will take 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)” |
Formulation in the parent study and the extension phase
“In the parent study, the dosage formulation of N-acetyl-l-leucine is 1000 mg powder for oral suspension (manufacture: Patheon UK Limited, Oxfordshire, UK) which is suspended in 40 mL Ora-Blend®.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the extension phase, the dosage form of N-acetyl-l-leucine is 1000 mg granules for oral suspension in a sachet (manufacture: Patheon UK Limited, Oxfordshire, UK, and Patheon France S.A.S., Bourgoin, France) which is suspended in 40 mL water.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Timing with meals, dose reduction, and compliance
“Medication should be taken at least 30 min before or at least 2 h after a meal.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If adverse events are noted, patients are permitted to down-titrate to one-half their daily dose, at the direction of the investigator.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compliance will be assessed upon a review of the inventory of IB1001 bottles/sachets returned by patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Extension phase treatment periods
Permitted concomitant therapies
Study outcomes
Rationale for using clinical impression of change in severity as the primary endpoint
Definition of the primary endpoint
Sponsor rationale: heterogeneous presentation and an individually chosen anchor test
“Given the heterogeneity of symptoms, the appointment of a single symptom scale, such as either the 8-m walk test (8MWT) or the 9-hole peg test of the dominant hand (9HPT-D), as the primary outcome measure is not appropriate for patient populations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary anchor test remains fixed for each patient for the duration of the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Finally, the CI-CS is a platform to capture and assess small but clinically meaningful changes in patient’s performance, which relate to their level of functioning and quality of life, but which cannot be obtained from the quantitative timed 8MWT or 9HPT-D assessments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sponsor rationale: use of the CI-CS in place of the SARA
Scoring by two raters and adjudication
“If there is a difference of one (1) point in the two primary blinded raters’ CI-CS scores for a specific video pairing, the two scores will be averaged.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If there is a difference greater than one (1) point between the two primary blinded reviewers’ CI-CS scores for a specific video pairing, an adjudication rating will be triggered.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Key secondary endpoint: Clinical Impression of Severity
Other secondary endpoints
Extension phase primary endpoint in the 2021 master protocol
“In the extension phase, the primary endpoint is defined as success on the Clinical Impression of Change in Severity© (CI-CS) comparing videos of the primary anchor test at (i) the end of the extension phase treatment with N-acetyl-l-leucine (visit 9) versus (ii) the extension phase baseline (visit 7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Extension phase primary endpoint in protocol version 7.0
Extension phase endpoints as presented
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment
| Population | Planned number |
|---|---|
| Enrolled | “To be enrolled: Approximately 39 patients” |
| Per protocol analysis | “To be analyzed according to the Per Protocol Analysis: Approximately 30 patients” |
Sample size assumptions and power
Extension phase sample size
Description of analysis sets
Modified intention-to-treat analysis set
Safety and per protocol sets
“Analyses will also be conducted on the per protocol analysis set which will consist of all patients with video recordings at baseline (visit 1 and/or visit 2), end of treatment (visit 3 and/or visit 4), and end of washout (visit 5 and/or visit 6) and without any major protocol deviations that can influence the validity of the data for the primary efficacy variable.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Planned primary analysis and multiplicity
“The analysis of the primary endpoint will be based on a single sample one-sided t test comparing the mean of the CI-CS differences with zero.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The null hypothesis is that the mean is ≤ 0, with the alternative hypothesis that this mean is > 0, and the test will be conducted at the one-sided 5% significance level.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All other endpoints will be evaluated descriptively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There will be no formal control of multiplicity across these endpoints.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Handling of missing video recordings
“If the visit 2 video is missing, the visit 1 video will be used in its place.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Analyses based on the mITT analysis set will utilize a last observation carried forward approach for missing videos 5 and 6.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the primary endpoint CI-CS, this implies that the CI-CS value for visit 4 to visit 6 will be assigned the value 0 if both videos 5 and 6 are not available.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Extension phase analysis set and planned test
Results
Participant disposition
Reasons for not completing
| Study period | Reason | Participants |
|---|---|---|
| Treatment with IB1001 | “Adverse Event” | “1” |
| Extension phase | “Adverse Event” | “1” |
| Extension phase | “Withdrawal by Subject” | “1” |
| Extension phase | “Lost to Follow-up” | “1” |
Prior use of prohibited medications and consent to the extension phase
Participants with extension phase assessments
Baseline characteristics
Clinical Global Impression of Severity at the baseline visits
Efficacy results
Primary endpoint: CI-CS during treatment minus CI-CS during washout
| Measure | Value |
|---|---|
| Participants analyzed | “16” |
| Mean (standard deviation), score on a scale | “0.16 (1.65)” |
Components of the primary endpoint
| Period | CI-CS, mean (standard deviation) |
|---|---|
| Treatment with IB1001 (Visit 4 versus Visit 2) | “0.16 (0.81)” |
| Post-treatment washout (Visit 6 versus Visit 4) | “0.00 (1.18)” |
Key secondary endpoint: change in Clinical Impression of Severity
| Measure | Value |
|---|---|
| Participants analyzed | “16” |
| Mean (standard deviation), score on a scale | “-0.09 (0.39)” |
CI-CS for the non-primary anchor test
| Period | CI-CS, mean (standard deviation) |
|---|---|
| Treatment with IB1001 | “0.00 (1.07)” |
| Post-treatment washout | “0.17 (1.03)” |
Change in SARA total score
| Period | Change, mean (standard deviation) |
|---|---|
| Treatment with IB1001 | “-0.31 (3.47)” |
| Post-treatment washout | “0.59 (2.99)” |
Change in SCAFI total score
| Period | Change, mean (standard deviation) |
|---|---|
| Treatment with IB1001 | “0.0583 (0.3384)” |
| Post-treatment washout | “0.0157 (0.1923)” |
Sponsor summary of the parent study results
Extension phase: change in SARA after 1 year of treatment
Extension phase: change in SARA during the washout and after a second year
Extension phase: comparison with a natural history cohort
Health-related quality of life and patient-reported outcomes
Change in EQ-5D visual analogue scale
| Period | Change, mean (standard deviation) |
|---|---|
| Treatment with IB1001 | “4.9 (9.7)” |
| Post-treatment washout | “-0.8 (10.5)” |
Caregiver and participant Clinical Global Impression of Severity by visit
Safety results
Deaths, serious adverse events, and other adverse events by period
| Category | Treatment with IB1001 | Post-treatment washout | Extension phase |
|---|---|---|---|
| All-cause mortality | “0/17 (0.00%)” | “0/17 (0.00%)” | “1/13 (7.69%)” |
| Serious adverse events | “1/17 (5.88%)” | “0/17 (0.00%)” | “2/13 (15.38%)” |
| Other (not including serious) adverse events | “9/17 (52.94%)” | “2/17 (11.76%)” | “11/13 (84.62%)” |
Serious adverse events by term
| Event | Treatment with IB1001 | Post-treatment washout | Extension phase | Severity and relatedness |
|---|---|---|---|---|
| Gastrointestinal lymphoma | “1/17 (5.88%)” | “0/17 (0.00%)” | “0/13 (0.00%)” | “severe, not related” |
| Peritoneal mesothelioma malignant | “0/17 (0.00%)” | “0/17 (0.00%)” | “1/13 (7.69%)” | “severe, not related” |
| Intraductal proliferative breast lesion | “0/17 (0.00%)” | “0/17 (0.00%)” | “1/13 (7.69%)” | “moderate, not related” |
| Infection | “0/17 (0.00%)” | “0/17 (0.00%)” | “1/13 (7.69%)” | “severe, not related” |
| Mastitis | “0/17 (0.00%)” | “0/17 (0.00%)” | “1/13 (7.69%)” | “severe, not related” |
| Seroma | “0/17 (0.00%)” | “0/17 (0.00%)” | “1/13 (7.69%)” | “severe, not related” |
| Erythema | “0/17 (0.00%)” | “0/17 (0.00%)” | “1/13 (7.69%)” | “severe, not related” |
Non-serious adverse events reported during the parent study
| Event | Treatment with IB1001 | Post-treatment washout |
|---|---|---|
| Abdominal pain upper | “2/17 (11.76%)” | “1/17 (5.88%)” |
| Nasopharyngitis | “1/17 (5.88%)” | “0/17 (0.00%)” |
| Oral herpes | “1/17 (5.88%)” | “0/17 (0.00%)” |
| Respiratory tract infection | “1/17 (5.88%)” | “0/17 (0.00%)” |
| Upper respiratory tract infection | “1/17 (5.88%)” | “0/17 (0.00%)” |
| Chorea | “1/17 (5.88%)” | “0/17 (0.00%)” |
| Syncope | “1/17 (5.88%)” | “0/17 (0.00%)” |
| Fatigue | “1/17 (5.88%)” | “0/17 (0.00%)” |
| Hypertransaminasaemia | “1/17 (5.88%)” | “0/17 (0.00%)” |
| Pollakiuria | “1/17 (5.88%)” | “0/17 (0.00%)” |
| Menstruation irregular | “1/17 (5.88%)” | “0/17 (0.00%)” |
| Cough | “1/17 (5.88%)” | “0/17 (0.00%)” |
| Hyperhydrosis | “1/17 (5.88%)” | “0/17 (0.00%)” |
| Gastrointestinal lymphoma | “1/17 (5.88%)” | “0/17 (0.00%)” |
| Diarrhoea | “0/17 (0.00%)” | “1/17 (5.88%)” |
| Muscle spasms | “0/17 (0.00%)” | “1/17 (5.88%)” |
Non-serious adverse events reported during the extension phase
| Event | Extension phase |
|---|---|
| Diarrhoea | “3/13 (23.08%)” |
| Nasopharyngitis | “2/13 (15.38%)” |
| Respiratory tract infection | “1/13 (7.69%)” |
| Bronchitis | “1/13 (7.69%)” |
| Candida infection | “1/13 (7.69%)” |
| Corona virus infection | “1/13 (7.69%)” |
| Dysphagia | “1/13 (7.69%)” |
| Vomiting | “1/13 (7.69%)” |
| Gait disturbance | “1/13 (7.69%)” |
| Fall | “1/13 (7.69%)” |
| Hand fracture | “1/13 (7.69%)” |
| B-lymphocyte count abnormal | “1/13 (7.69%)” |
| T-lymphocyte count abnormal | “1/13 (7.69%)” |
| Type 2 diabetes mellitus | “1/13 (7.69%)” |
| Muscle spasms | “1/13 (7.69%)” |
| Myalgia | “1/13 (7.69%)” |
| Speech disorder | “1/13 (7.69%)” |
| Tremor | “1/13 (7.69%)” |
| Micturition urgency | “1/13 (7.69%)” |
Adverse events the sponsor considered related to the study drug
Study limitations
Summary
IB1001-203 was a single-group, open-label trial in which each participant's 6-week post-treatment washout served as the comparison for the 6-week treatment period. Blinded raters scored the primary endpoint from video recordings; the SARA, the SCAFI, and the clinical global impression scales were recorded at the study sites under open-label conditions. The protocol planned approximately 39 enrolled participants and calculated 76% power with 30 participants. The sponsor terminated the trial after 17 participants were enrolled, and 16 were analyzed. The registry posts a mean and standard deviation for each endpoint and no statistical test. The posted primary endpoint was a mean of 0.16 (standard deviation 1.65), and on the 3-point reclassification 8 of 16 participants were rated improved after treatment and 8 of 16 after washout. The extension phase was unblinded. Its primary endpoint was the CI-CS in the 2021 master protocol and the SARA in protocol version 7.0. Extension phase efficacy results are available from a conference abstract covering 12 participants at 1 year and 7 participants at 2 years, and the abstract does not describe the natural history cohort used for its comparison of progression rates.
Limitations and caveats posted by the sponsor
No correction for multiple comparisons
Mashhad N-acetyl-L-leucine crossover trial
Objective
Background to the trial
“Although N-acetyl-dl-leucine (ADLL) has shown some efficacy in patients with AT, its more pharmacologically active enantiomer, N-acetyl-l-leucine (NALL), has just recently been investigated in ataxic individuals.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Recruitment site and enrollment period
Registry record
| Field | Quoted record |
|---|---|
| Registration number | “IRCT20210413050958N1” |
| Registration date | “2021-10-27, 1400/08/05” |
| Registration timing | “prospective” |
| Recruitment status | “Recruitment complete” |
| Expected recruitment start date | “2021-12-06, 1400/09/15” |
| Expected recruitment end date | “2022-08-06, 1401/05/15” |
| Recruitment center | “Ghaem Hospital” |
| City | “Mashhad” |
| Sponsor and funding source | “Mashhad University of Medical Sciences” |
Study design
Randomized, double-blind, placebo-controlled, two-period crossover trial
“This 2 × 2 crossover, double-blind, randomized clinical trial was conducted on 20 patients with AT.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Subjects then had a 4-week washout before crossing over to the other treatment for an additional six weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
| Design field | Quoted record |
|---|---|
| Phase | “2” |
| Assignment | “Crossover” |
| Placebo | “Used” |
| Blinding (investigator's opinion) | “Triple blinded” |
| Target sample size | “16” |
Randomization stratified by sex
Blinding and placebo matching
Eligibility criteria
Registry inclusion criteria
Registry exclusion criteria
Genetic diagnosis in the randomized participants
“After excluding four patients, 16 subjects (eight females, eight males; mean age 9.8 ± 3.5 years) with a definitive genetic diagnosis of AT were randomly assigned to one of two study groups, with one group receiving 1-4 g/day NALL or a placebo for six weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
N-acetyl-L-leucine and placebo regimens
Changes to formulation and dose recorded in the registry update
Study outcomes
Rationale for using SARA and SCAFI scores as the primary endpoints
Primary outcome and its measurement
| Field | Quoted record |
|---|---|
| Description | “Movement signs” |
| Timepoint | “Before the intervention and 6 weeks after taking supplement or placebo in every study stage” |
| Method of measurement | “Using the Scale for Assessment and Rating of Ataxia (SARA) score and Spinocerebellar Ataxia Functional Index (SCAFI)” |
Secondary outcomes
Systematic review comment on ataxia scales in ataxia-telangiectasia
Statistical analysis description
Number of participants (Planned and analyzed)
Target sample size and participants randomized
Description of analysis sets
Availability of the statistical analysis plan
| Document | Registry sharing plan |
|---|---|
| Statistical analysis plan | “No - There is not a plan to make this available” |
| Study protocol | “Yes - There is a plan to make this available” |
Results
Participant disposition
Exclusions before randomization
“After excluding four patients, 16 subjects (eight females, eight males; mean age 9.8 ± 3.5 years) with a definitive genetic diagnosis of AT were randomly assigned to one of two study groups, with one group receiving 1-4 g/day NALL or a placebo for six weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Sex and age of the randomized participants
| Characteristic | Value |
|---|---|
| Participants randomized | “16 subjects”View highlighted excerpt for this quote |
| Sex | “eight females, eight males”View highlighted excerpt for this quote |
| Age | “mean age 9.8 ± 3.5 years”View highlighted excerpt for this quote |
Efficacy results
Ataxia outcomes
“Although patients' nausea and constipation were improved, the results failed to reveal any significant benefits of NALL treatment on ataxia symptoms.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“NALL treatment had no significant effects on SARA, SCAFI-9HPT (9-hole peg test) nondominant, SCAFI-9HPT dominant, or SCAFI-8WMT (8 m walking time) (p > 0.05).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Authors' conclusion
“To the best of our knowledge, this was the first placebo-controlled, randomized clinical trial exploring NALL's potential effects for treating AT.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Despite improvements in some symptomss, NALL intervention failed to improve motor function significantly.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
PedsQL physical health score
“Quality of life (QOL) was evaluated by a specialist using the PedsQL questionnaire.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Our patient's Physical Health score in Child self-report and Parent proxy-report did not significantly change in the treatment group compared to the placebo (p > 0.05).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Safety results
Safety assessment and reported side effects
“Fasting blood samples were taken from all subjects before and after each intervention to determine potential side effects.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“None of the volunteers reported serious or moderate side effects.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary
The trial randomized 16 participants at one hospital after 4 of 20 were excluded, with 6-week treatment periods separated by a 4-week washout. The participants had a mean age of 9.8 years. The abstract reports the comparisons with placebo as p > 0.05 and gives no effect estimates, confidence intervals, or scores by period. The registry names Hubei ipure Biotech as the source of the N-acetyl-L-leucine caplets, dosed at 1 to 4 g per day by weight, and states that no statistical analysis plan will be shared. A 2026 systematic review rated the trial as having “some concerns” on the RoB 2 tool and listed limited duration and a potential carry-over effect as its limitations. The evidence quoted here comes from the article's abstract and the registry record.
Risk of bias assessment in a systematic review
| Item | Assessment |
|---|---|
| Risk of bias (RoB 2) | “Some concerns”View highlighted excerpt for this quote |
| Limitations | “Limited duration; potential carry‐over effect”View highlighted excerpt for this quote |
Acetyl-DL-leucine case series
Objective
Hypothesis
Location and study date
Study design
Uncontrolled case series with assessments before and during treatment
“Six patients were treated with ADLL 3 g/day for 1 week followed by 5g/day for 3 weeks to 1 year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Measurements took place at baseline, at 1 month of therapy in 5 patients, and after 6 and 12 months in 1 patient.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Treatment
Study outcomes
Rationale for using SARA total score as an efficacy outcome
Ataxia scales and video-oculography
“Cerebellar ataxia was evaluated by validated scales.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Gaze-holding, saccades and smooth pursuit were examined by video-oculography.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Participants treated and assessed
| Population | Participants |
|---|---|
| Treated with acetyl-DL-leucine | “Six patients”View highlighted excerpt for this quote |
| Assessed at 1 month of therapy | “5 patients”View highlighted excerpt for this quote |
| Assessed after 6 and 12 months | “1 patient”View highlighted excerpt for this quote |
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Baseline SARA score and oculomotor findings
| Characteristic | Value |
|---|---|
| SARA at baseline, mean (SD, minimum to maximum) | “22.1 (5.88, 11-28.5)”View highlighted excerpt for this quote |
| Slow-phase velocity of downbeat nystagmus at baseline | “5.57°/s (1.8, 3.53-6.99)”View highlighted excerpt for this quote |
Efficacy results
SARA total score after 1 month
Downbeat nystagmus after 1 month
Health-related quality of life and patient-reported outcomes
Safety results
Study limitations
Summary
The series included six participants treated open label with the racemate acetyl-DL-leucine and had no control group. Follow-up measurements were made at 1 month in 5 participants and at 6 and 12 months in 1 participant. The abstract reports no adverse event or quality-of-life results. A 2026 systematic review rated the quality of the study as low on the National Institutes of Health tool for studies without a control group and listed limited duration and incomplete assessment in some cases as its limitations. The evidence quoted here comes from the article's abstract.
Quality assessment in a systematic review
Acetyl-DL-leucine case report
Objective
Background to the report
Location and study date
Study design
Single-participant report with scheduled assessments
“Additionally, The Scale for the Assessment and Rating of Ataxia (SARA) score was used to assess the drug's effects on ataxia symptoms at baseline, 6, 12, and 16 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Safety was assessed via clinical blood chemistry prior to the intervention and after 6 and 16 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Not applicable.
Treatment
Study outcomes
Rationale for using SARA score as an efficacy outcome
Outcome measures
“Additionally, The Scale for the Assessment and Rating of Ataxia (SARA) score was used to assess the drug's effects on ataxia symptoms at baseline, 6, 12, and 16 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Quality of life has also been evaluated by a specialist using the PedsQL questionnaire.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Individual participant
Description of analysis sets
Not applicable.
Results
Participant disposition
No evidence found.
Baseline characteristics
Age and sex
| Characteristic | Value |
|---|---|
| Participant | “a 9-year-old female with AT”View highlighted excerpt for this quote |
Efficacy results
Health-related quality of life and patient-reported outcomes
Safety results
Tolerability and blood chemistry
Study limitations
Summary
The report describes one participant, a 9-year-old girl, treated with the racemate N-acetyl-DL-leucine at 4 g per day for 16 weeks without a comparator. The abstract gives the change in SARA score (11.0 points, 48.88%) without the baseline score and does not describe blinding of the assessor. Nausea and constipation occurred in the first week. The evidence quoted here comes from the article's abstract.